Several clinical trials are currently being conducted to evaluate the effectiveness of CTAs, such as NY-ESO-1, MAGE, MSLN, PRAME, PSCA, ROR2 and WT1, as treatment targets in breast cancers and other solid tumours (Table 2). The gene discussed is PSCA; the disease is breast carcinoma.